The author discusses the production and marketing of the drug BiDil manufactured by pharmaceutical firm NitroMed Inc., in which the drug is said to be the first race-specific drug in the field of genomics. She explores the medical practices and classification behind the production of the drug, drawing attention to the new dominant ideology, epistmeic trafficking. She examines the epistemic trafficking performed at the production of the BiDil drug.